<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Date of report (Date of earliest event
reported): <U>February 27, 2012</U></B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B><U>SeraCare Life Sciences, Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Exact Name of Registrant as Specified in
Charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; padding-right: 1.75pt; padding-left: 1.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Delaware</B></P></TD>
    <TD STYLE="width: 5%; padding-right: 1.75pt; padding-left: 1.75pt; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 30%; padding-right: 1.75pt; padding-left: 1.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.5pt solid"><B>001-34105</B></P></TD>
    <TD STYLE="width: 5%; padding-right: 1.75pt; padding-left: 1.75pt; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 30%; padding-right: 1.75pt; padding-left: 1.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.5pt solid"><B>33-0056054</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(State or other jurisdiction</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>of incorporation) </B></P></TD>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; font-size: 10pt; font-weight: bold; text-align: center">(Commission file number)</TD>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="padding-right: 1.75pt; padding-left: 1.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(IRS Employer</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Identification No.)</B></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B><U>37 Birch Street, Milford, Massachusetts
01757</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">Registrant&rsquo;s telephone number,
including area code: <B><U>(508) 244-6400</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B><U>Not Applicable</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Former name or former address, if changed since
last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 22.5pt"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 22.5pt"><FONT STYLE="font-family: Wingdings">x</FONT></TD><TD>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.142-12)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 22.5pt"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 22.5pt"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; background-color: white"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; background-color: white"><B>Item 1.01&#9;Entry into
a Material Definitive Agreement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Amendment to Agreement and Plan of Merger</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On February 27, 2012, SeraCare Life Sciences,
Inc., a Delaware corporation (the &ldquo;Company&rdquo;), entered into an amendment (the &ldquo;Amendment&rdquo;) to the Agreement
and Plan of Merger dated February 12, 2012 (the &ldquo;Merger Agreement&rdquo;) by and among the Company, Project Plasma Holdings
Corporation, a Delaware corporation (&ldquo;Parent&rdquo;), and Project Plasma Merger Corp., a Delaware corporation and a wholly
owned subsidiary of Parent (&ldquo;Merger Sub&rdquo;) providing for the merger of Merger Sub with and into the Company (the &ldquo;Merger&rdquo;),
with the Company surviving the Merger as a wholly owned subsidiary of Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Amendment was entered into to amend and
restate the form of certificate of incorporation of the surviving corporation of the Merger to substantially conform its indemnification
and advancement of expenses provisions to those included in the Company&rsquo;s currently effective certificate of incorporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The foregoing description of the Amendment does
not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Amendment attached hereto
as Exhibit 2.2, which is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><U>Cautionary Statement Regarding Forward-Looking Statements</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We caution you that this document may contain
disclosures that are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about
the Company and the Merger. Forward-looking statements include statements in which we use words such as &quot;expect,&quot; &quot;believe,&quot;
&quot;anticipate,&quot; &quot;intend,&quot; or similar expressions. These forward-looking statements are based upon information
presently available to the Company&rsquo;s management and are inherently subjective, uncertain and subject to change, due to any
number of risks and uncertainties. Factors that could cause events not to occur as expressed in the forward-looking statements
in this document include, but are not limited to, unanticipated delays; the occurrence of any event, change or other circumstances
that could give rise to the termination of the Merger Agreement; the outcome of any legal proceedings that may be instituted with
respect to the Merger; and the inability to complete the Merger due to the failure to obtain the Shareholder Approval or the failure
to satisfy other closing conditions, including the receipt of required regulatory approvals, as well as other risk factors detailed
in the Company&rsquo;s Annual Report on Form 10-K filed with the SEC on November 21, 2011, as amended, under the captions &ldquo;Cautionary
Note Regarding Forward-Looking Statements&rdquo; and &ldquo;Risk Factors&rdquo; and otherwise in the Company&rsquo;s reports and
filings with the Securities and Exchange Commission. Many of these factors are beyond the Company&rsquo;s ability to control or
predict. You should not place undue reliance on any forward-looking statements, since those statements speak only as of the date
that they are made. The Company assumes no obligation to update, revise or correct any forward-looking statements after the date
of this document or after the respective dates on which such statements otherwise are made, whether as a result of new information,
future events or otherwise, except as otherwise may be required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><U>Additional Information about the Merger and Where to Find
It</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">This document may be deemed to be solicitation
material with respect to the Merger. In connection with the Merger, the Company intends to file a preliminary proxy statement and
file or furnish other relevant materials with the Securities and Exchange Commission, or the SEC. Once the SEC completes its review
of the preliminary proxy statement, a definitive proxy statement and a form of proxy will be filed with the SEC and mailed to the
shareholders of the Company. THE COMPANY&rsquo;S INVESTORS AND SECURITY HOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY
ALL RELEVANT MATERIALS FILED OR FURNISHED WITH THE SEC, INCLUDING THE PROXY STATEMENT WHEN IT BECOMES AVAILABLE, BECAUSE THESE
MATERIALS WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED MERGER AND THE PARTIES TO THE MERGER. The proxy statement and other
relevant materials (when they become available), and any and all documents filed or furnished by the Company with or to the SEC,
may be obtained free of charge at the SEC&rsquo;s web site at www.sec.gov. In addition, the Company&rsquo;s investors and security
holders may obtain free copies of the documents filed or furnished by the Company with or to the SEC by directing a written request
to SeraCare Life Sciences, Inc., 37 Birch Street, Milford, MA 01757, Attention: Corporate Secretary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><U>Participants in the Solicitation</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Company and its executive officers and directors
may be deemed to be participants in the solicitation of proxies from the shareholders of the Company with respect to the special
meeting of shareholders that will be held to consider the Merger. Information about those executive officers and directors of the
Company and their ownership of the Company&rsquo;s common stock is set forth in Amendment No. 1 to the Company&rsquo;s Annual Report
on Form 10-K for the fiscal year ended September 30, 2011, which was filed with the SEC on January 30, 2012, and is supplemented
by other public filings made, and to be made, with the SEC by the Company. Information regarding the direct and indirect interests
of the Company, its executive officers and directors and other participants in the solicitation, which may, in some cases, be different
from those of the Company&rsquo;s security holders generally, will be set forth in the proxy statement relating to the Merger when
it becomes available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 9.01</B></TD><TD><B>Financial Statements and Exhibits.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;(d) &#9;<U>Exhibits</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; font-weight: bold; text-decoration: underline">Exhibit No.</TD>
    <TD STYLE="width: 90%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; font-weight: bold; text-decoration: underline">Description</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 6pt 6.7pt 12pt 0.12in; font-size: 10pt">2.1</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 12pt; font-size: 10pt; padding-left: 0.12in">Agreement and Plan of Merger, dated February 12, 2012, among Project Plasma Holdings Corporation, Project Plasma Merger Corp. and SeraCare Life Sciences, Inc. (incorporated by reference to Exhibit 2.1 of the Company&rsquo;s current report on Form 8-K, event date February 12, 2012, filed on February 14, 2012)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 6pt 6.7pt 12pt 0.12in; font-size: 10pt">2.2</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 12pt; font-size: 10pt; padding-left: 0.12in">Amendment No. 1, dated February 27, 2012, to Agreement and Plan of Merger, dated February 12, 2012, among Project Plasma Holdings Corporation, Project Plasma Merger Corp. and SeraCare Life Sciences, Inc.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in; text-indent: 0.5in">SERACARE LIFE SCIENCES, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in; text-indent: 0.5in">By: <U>/s/ Gregory A. Gould</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in; text-indent: 0.5in">Name: Gregory A. Gould</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3in">Title: Interim President and Chief Executive Officer,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3in">Chief Financial Officer, Secretary and Treasurer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Dated: February 27, 2012</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 24pt; text-align: center"><B>EXHIBIT INDEX</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; font-weight: bold; text-decoration: underline">Exhibit No.</TD>
    <TD STYLE="width: 90%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; font-weight: bold; text-decoration: underline">Description</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 6pt 6.7pt 12pt 0.12in; font-size: 10pt">2.1</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 12pt; font-size: 10pt; padding-left: 0.12in">Agreement and Plan of Merger, dated February 12, 2012, among Project Plasma Holdings Corporation, Project Plasma Merger Corp. and SeraCare Life Sciences, Inc. (incorporated by reference to Exhibit 2.1 of the Company&rsquo;s current report on Form 8-K, event date February 12, 2012, filed on February 14, 2012)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 6pt 6.7pt 12pt 0.12in; font-size: 10pt">2.2</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 12pt; font-size: 10pt; padding-left: 0.12in">Amendment No. 1, dated February 27, 2012, to Agreement and Plan of Merger, dated February 12, 2012, among Project Plasma Holdings Corporation, Project Plasma Merger Corp. and SeraCare Life Sciences, Inc.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v303991_8-k.htm", "description": "CURRENT REPORT", "secsgml_size_bytes": 23754}]
{"company-data": {"conformed-name": "SERACARE LIFE SCIENCES INC", "cik": "0001156295", "assigned-sic": "2835", "irs-number": "330056054", "fiscal-year-end": "0930"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-34105", "film-number": "12644173"}, "business-address": {"street1": "37 BIRCH STREET", "city": "MILFORD", "state": "MA", "zip": "01757", "phone": "5082446400"}, "mail-address": {"street1": "37 BIRCH STREET", "city": "MILFORD", "state": "MA", "zip": "01757"}}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of report (Date of earliest event
reported):
February 27, 2012
SeraCare Life Sciences, Inc.
(Exact Name of Registrant as Specified in
Charter)
Delaware
001-34105
33-0056054
(State or other jurisdiction
of incorporation)
(Commission file number)
(IRS Employer
Identification No.)
37 Birch Street, Milford, Massachusetts
01757
(Address of principal executive offices)
Registrant's telephone number,
including area code:
(508) 244-6400
Not Applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
x
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.142-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01	Entry into
a Material Definitive Agreement.
Amendment to Agreement and Plan of Merger
On February 27, 2012, SeraCare Life Sciences,
Inc., a Delaware corporation (the "Company"), entered into an amendment (the "Amendment") to the Agreement
and Plan of Merger dated February 12, 2012 (the "Merger Agreement") by and among the Company, Project Plasma Holdings
Corporation, a Delaware corporation ("Parent"), and Project Plasma Merger Corp., a Delaware corporation and a wholly
owned subsidiary of Parent ("Merger Sub") providing for the merger of Merger Sub with and into the Company (the "Merger"),
with the Company surviving the Merger as a wholly owned subsidiary of Parent.
The Amendment was entered into to amend and
restate the form of certificate of incorporation of the surviving corporation of the Merger to substantially conform its indemnification
and advancement of expenses provisions to those included in the Company's currently effective certificate of incorporation.
The foregoing description of the Amendment does
not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Amendment attached hereto
as Exhibit 2.2, which is incorporated herein by reference.
Cautionary Statement Regarding Forward-Looking Statements
We caution you that this document may contain
disclosures that are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about
the Company and the Merger. Forward-looking statements include statements in which we use words such as "expect," "believe,"
"anticipate," "intend," or similar expressions. These forward-looking statements are based upon information
presently available to the Company's management and are inherently subjective, uncertain and subject to change, due to any
number of risks and uncertainties. Factors that could cause events not to occur as expressed in the forward-looking statements
in this document include, but are not limited to, unanticipated delays; the occurrence of any event, change or other circumstances
that could give rise to the termination of the Merger Agreement; the outcome of any legal proceedings that may be instituted with
respect to the Merger; and the inability to complete the Merger due to the failure to obtain the Shareholder Approval or the failure
to satisfy other closing conditions, including the receipt of required regulatory approvals, as well as other risk factors detailed
in the Company's Annual Report on Form 10-K filed with the SEC on November 21, 2011, as amended, under the captions "Cautionary
Note Regarding Forward-Looking Statements" and "Risk Factors" and otherwise in the Company's reports and
filings with the Securities and Exchange Commission. Many of these factors are beyond the Company's ability to control or
predict. You should not place undue reliance on any forward-looking statements, since those statements speak only as of the date
that they are made. The Company assumes no obligation to update, revise or correct any forward-looking statements after the date
of this document or after the respective dates on which such statements otherwise are made, whether as a result of new information,
future events or otherwise, except as otherwise may be required by law.
Additional Information about the Merger and Where to Find
It
This document may be deemed to be solicitation
material with respect to the Merger. In connection with the Merger, the Company intends to file a preliminary proxy statement and
file or furnish other relevant materials with the Securities and Exchange Commission, or the SEC. Once the SEC completes its review
of the preliminary proxy statement, a definitive proxy statement and a form of proxy will be filed with the SEC and mailed to the
shareholders of the Company. THE COMPANY'S INVESTORS AND SECURITY HOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY
ALL RELEVANT MATERIALS FILED OR FURNISHED WITH THE SEC, INCLUDING THE PROXY STATEMENT WHEN IT BECOMES AVAILABLE, BECAUSE THESE
MATERIALS WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED MERGER AND THE PARTIES TO THE MERGER. The proxy statement and other
relevant materials (when they become available), and any and all documents filed or furnished by the Company with or to the SEC,
may be obtained free of charge at the SEC's web site at www.sec.gov. In addition, the Company's investors and security
holders may obtain free copies of the documents filed or furnished by the Company with or to the SEC by directing a written request
to SeraCare Life Sciences, Inc., 37 Birch Street, Milford, MA 01757, Attention: Corporate Secretary.
Participants in the Solicitation
The Company and its executive officers and directors
may be deemed to be participants in the solicitation of proxies from the shareholders of the Company with respect to the special
meeting of shareholders that will be held to consider the Merger. Information about those executive officers and directors of the
Company and their ownership of the Company's common stock is set forth in Amendment No. 1 to the Company's Annual Report
on Form 10-K for the fiscal year ended September 30, 2011, which was filed with the SEC on January 30, 2012, and is supplemented
by other public filings made, and to be made, with the SEC by the Company. Information regarding the direct and indirect interests
of the Company, its executive officers and directors and other participants in the solicitation, which may, in some cases, be different
from those of the Company's security holders generally, will be set forth in the proxy statement relating to the Merger when
it becomes available.
Item 9.01
Financial Statements and Exhibits.
(d)
Exhibits
.
Exhibit No.
Description
2.1
Agreement and Plan of Merger, dated February 12, 2012, among Project Plasma Holdings Corporation, Project Plasma Merger Corp. and SeraCare Life Sciences, Inc. (incorporated by reference to Exhibit 2.1 of the Company's current report on Form 8-K, event date February 12, 2012, filed on February 14, 2012)
2.2
Amendment No. 1, dated February 27, 2012, to Agreement and Plan of Merger, dated February 12, 2012, among Project Plasma Holdings Corporation, Project Plasma Merger Corp. and SeraCare Life Sciences, Inc.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SERACARE LIFE SCIENCES, INC.
By:
/s/ Gregory A. Gould
Name: Gregory A. Gould
Title: Interim President and Chief Executive Officer,
Chief Financial Officer, Secretary and Treasurer
Dated: February 27, 2012
EXHIBIT INDEX
Exhibit No.
Description
2.1
Agreement and Plan of Merger, dated February 12, 2012, among Project Plasma Holdings Corporation, Project Plasma Merger Corp. and SeraCare Life Sciences, Inc. (incorporated by reference to Exhibit 2.1 of the Company's current report on Form 8-K, event date February 12, 2012, filed on February 14, 2012)
2.2
Amendment No. 1, dated February 27, 2012, to Agreement and Plan of Merger, dated February 12, 2012, among Project Plasma Holdings Corporation, Project Plasma Merger Corp. and SeraCare Life Sciences, Inc.